Abuse-Deterrent Opioids: ICER Value Analysis Could Reinforce Coverage Restrictions
Executive Summary
Draft report concludes that added cost of abuse-deterrent opioids is not outweighed by reductions to health care system costs resulting from their use.
You may also be interested in...
ICER And The VA: Match Made in Heaven?
Institute for Clinical and Economic Review partners with the US Department of Veterans Affairs to support the agency's approach to negotiating and contracting for prescription drugs.
Value Vs. Values: ICER’s Review Of Opioid Abuse-Deterrent Formulations
The Institute for Clinical & Economic Review is setting an appropriately broad scope in its review of the abuse-deterrent opioid class. But the project opens up a much larger question of how broadly to define value – and how to weigh non-economic values – in cost-effectiveness reviews.
Part D Price Negotiation Round One: Several Likely Candidates May Not Feel The Cut
Heavily rebated drugs may already be meeting the price goals established by the Senate legislation. As a result, price negotiation for drugs covered under Part B are likely to yield greater savings to the Medicare program than Part D.